Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 120,000 shares at $51.16 ($6.2M) on 2025-09-04, disclosed to the SEC on 2025-09-08.
Scheduled sale ($6.2M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $51.15 | 14,525 | $743K | 11.9% |
| 2 | $51.15 | 14,525 | $743K | 11.9% |
| 3 | $51.16 | 14,558 | $745K | 12.0% |
| 4 | $51.16 | 14,558 | $745K | 12.0% |
| 5 | $51.85 | 5,442 | $282K | 4.5% |
| 6 | $51.85 | 5,442 |
| $282K |
| 4.5% |
| 7 | $51.85 | 5,475 | $284K | 4.6% |
| 8 | $51.85 | 5,475 | $284K | 4.6% |
| 9 | $51.95 | 2,300 | $119K | 1.9% |
| 10 | $51.96 | 2,300 | $120K | 1.9% |
| 11 | $53.16 | 16,800 | $893K | 14.3% |
| 12 | $53.16 | 16,900 | $898K | 14.4% |
| 13 | $53.80 | 800 | $43K | 0.7% |
| 14 | $53.80 | 900 | $48K | 0.8% |
| Total | $51.91 avg | 120,000 | $6.2M | 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |